Efficacy and safety results from a randomized, phase II trial of neoadjuvant capecitabine plus epirubicin plus cyclophosphamide vs 5-FU + epirubicin plus cyclophosphamide in operable breast cancer

被引：0
|
作者：
Roche, H.
Penault-Llorca, F.
Berton, Rigaud D.
Tubiana, Mathieu N.
Ferrero, J. M.
Coudert, B.
Mousseau, M.
Monnier, A.
Orfuevre, H.
Audhuy, B.
Rotarski, M.
Homokos, H.
Fumoleau, P.
机构：
[1] Inst Claudius Regaud, Toulouse, France
[2] Ctr Jean Perrin, Clermont Ferrand, France
[3] Ctr Rene Gauducheau, St Herblain, France
[4] Hop Dupuytren, Limoges, France
[5] Ctr Antoine Lacassagne, F-06054 Nice, France
[6] Ctr Georges Francois Leclerc, Dijon, France
[7] CHU Grenoble, La Tronche, France
[8] CH Montbeliard, Montbeliard, France
[9] CH Fleyriat, Bourg En Bresse, France
[10] Hop Louis Pasteur, Colmar, France
[11] Ctr Oncol Du Pays Basque, Bayonne, France
[12] Roche Neuilly, Neuilly Sur Seine, France
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S225 / S225
页数：1
相关论文
共 50 条
  • [41] Epirubicin plus cyclophosphamide vs. weekly paclitaxel as primary systemic therapy in patients with stage II and III breast cancer: randomized phase II study
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 156 - 156
  • [42] Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study
    Martin, Miguel
    Ruiz Simon, Amparo
    Ruiz Borrego, Manuel
    Ribelles, Nuria
    Rodriguez-Lescure, Alvaro
    Munoz-Mateu, Montserrat
    Gonzalez, Sonia
    Margeli Vila, Mireia
    Barnadas, Agusti
    Ramos, Manuel
    Del Barco Berron, Sonia
    Jara, Carlos
    Calvo, Lourdes
    Martinez-Janez, Noelia
    Mendiola Fernandez, Cesar
    Rodriguez, Cesar A.
    Martinez de Duenas, Eduardo
    Andres, Raquel
    Plazaola, Arrate
    de la Haba-Rodriguez, Juan
    Manuel Lopez-Vega, Jose
    Adrover, Encarna
    Isabel Ballesteros, Ana
    Santaballa, Ana
    Sanchez-Rovira, Pedro
    Baena-Canada, Jose M.
    Casas, Maribel
    del Carmen Camara, Mara
    Maria Carrasco, Eva
    Lluch, Ana
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3788 - +
  • [43] Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety
    E Baldini
    T Prochilo
    B Salvadori
    A Bolognesi
    D Aldrighetti
    M Venturini
    R Rosso
    F Carnino
    L Gallo
    P Giannessi
    P F Conte
    C Orlandini
    P Bruzzi
    British Journal of Cancer, 2004, 91 : 45 - 49
  • [44] Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety
    Baldini, E
    Prochilo, T
    Salvadori, B
    Bolognesi, A
    Aldrighetti, D
    Venturini, M
    Rosso, R
    Carnino, F
    Gallo, L
    Giannessi, P
    Conte, PF
    Orlandini, C
    Bruzzi, P
    BRITISH JOURNAL OF CANCER, 2004, 91 (01) : 45 - 49
  • [45] Comparing doxorubicin plus cyclophosphamide (four courses) and CMF (three more courses) with doxorubicin plus cyclophosphamide (four courses) and paclitaxel plus epirubicin (three courses) as adjuvant therapy for operable breast cancer
    Ghavamzadeh, A.
    Najafi, S. Nadjar
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] Neoadjuvant adriamycin plus cyclophosphamide followed by docetaxel (AC4-D4) vs 5-fluorouracil, epirubicin plus cyclophosphamide followed by docetaxel (FEC3-D3) in stage II or III operable breast cancer : Randomized phase III neo-shorter trial (NCT02001506)
    Hwang, Inhwan
    Kim, Jeong Eun
    Jeong, Jae Ho
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Son, Byung Ho
    Ahn, Sei-Hyun
    Lee, Hee Jin
    Gong, Gyungyub
    Kim, Sung-Bae
    CANCER RESEARCH, 2021, 81 (04)
  • [47] An interim safety analysis of ABCSG-24: 6 cycles of docetaxel, epirubicin, and capecitabine plus pegfilgrastim (DEC) vs. 6 cycles of docetaxel and epirubicin plus pegfilgrastim (DE) in the neoadjuvant treatment of operable breast cancer.
    Steger, G. G.
    Greil, R.
    Samonigg, H.
    Jakesz, R.
    Bartsch, R.
    Mlineritsch, B.
    Melbinger-Zeinitzer, E.
    Marth, C.
    Schippinger, W.
    Gnant, M. F.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S156 - S156
  • [48] Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial
    Jiahui Huang
    Yiwei Tong
    Jin Hong
    Ou Huang
    Jiayi Wu
    Jianrong He
    Weiguo Chen
    Yafen Li
    Xiaosong Chen
    Kunwei Shen
    Breast Cancer Research and Treatment, 2023, 197 : 525 - 533
  • [49] Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial
    Huang, Jiahui
    Tong, Yiwei
    Hong, Jin
    Huang, Ou
    Wu, Jiayi
    He, Jianrong
    Chen, Weiguo
    Li, Yafen
    Chen, Xiaosong
    Shen, Kunwei
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 197 (03) : 525 - 533
  • [50] Capecitabine plus Epirubicin plus Cyclophosphamide Combination Therapy (CEX Therapy) as Neoadjuvant Chemotherapy for HER-2-Negative Breast Cancer: A Retrospective, Single-Center Study
    Yokoyama, Tadashi
    Makino, Hiroshi
    Seki, Natsuki
    Ueda, Junji
    Hosone, Masaru
    Katayama, Hironori
    Takei, Hiroyuki
    Yoshida, Hiroshi
    JOURNAL OF NIPPON MEDICAL SCHOOL, 2020, 87 (02) : 73 - 79
12345